{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:13:12Z","timestamp":1789009992690,"version":"build-2803163510"},"reference-count":154,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"am","delay-in-days":344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["1U01HL163983"],"award-info":[{"award-number":["1U01HL163983"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA021765"],"award-info":[{"award-number":["P30 CA021765"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007737","name":"St. Jude Children's Research Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["1K99DK134844-01"],"award-info":[{"award-number":["1K99DK134844-01"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jcyt.2024.06.002","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T02:27:53Z","timestamp":1717640873000},"page":"1411-1420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["International Society for Cell &amp; Gene Therapy Stem Cell Engineering Committee report on the current state of hematopoietic stem and progenitor cell\u2013based genomic therapies and the challenges faced"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5679-5533","authenticated-orcid":false,"given":"Ashish O.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6982-0400","authenticated-orcid":false,"given":"Melissa","family":"Azul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-6549","authenticated-orcid":false,"given":"Senthil Velan","family":"Bhoopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2019-0887","authenticated-orcid":false,"given":"Allistair","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bertaina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6078-4028","authenticated-orcid":false,"given":"Alan","family":"Bidgoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmem","family":"Bonfim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"DeZern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-9753","authenticated-orcid":false,"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrystal U.","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Purtill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap Jan","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Prockop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-2081","authenticated-orcid":false,"given":"Akshay","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.06.002_bib0001","doi-asserted-by":"crossref","first-page":"1004.e1","DOI":"10.1016\/j.jtct.2021.09.009","article-title":"Haploidentical allogeneic stem cell transplantation in sickle cell disease: a systematic review and meta-analysis","volume":"27","author":"Aydin","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0002","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","article-title":"Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study","volume":"6","author":"Eapen","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0003","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13023-015-0313-y","article-title":"Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report","volume":"10","author":"Boucher","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0004","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.bbmt.2018.09.036","article-title":"Survival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation","volume":"25","author":"Raymond","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0140-6736(23)00731-6","article-title":"Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium","volume":"402","author":"Thakar","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0006","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/191387a0","article-title":"Incorporation of deoxyribonucleic acid by mammalian cells in vitro","volume":"191","author":"Kay","year":"1961","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0007","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1073\/pnas.60.4.1288","article-title":"The integrated state of viral DNA in SV40-transformed cells","volume":"60","author":"Sambrook","year":"1968","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0008","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-mediated gene therapy for research and therapeutic purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu Rev Virol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0009","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.3864246","article-title":"Retroviral vector-mediated gene transfer into human hematopoietic progenitor cells","volume":"230","author":"Gruber","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0010","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1073\/pnas.83.17.6563","article-title":"Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer","volume":"83","author":"Kantoff","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0011","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/310476a0","article-title":"Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse","volume":"310","author":"Williams","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0012","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1073\/pnas.83.8.2566","article-title":"Retrovirus-mediated transfer of human adenosine deaminase gene sequences into cells in culture and into murine hematopoietic cells in vivo","volume":"83","author":"Williams","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0013","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0014","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0015","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0016","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0017","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0018","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nbt0997-871","article-title":"Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo","volume":"15","author":"Zufferey","year":"1997","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0019","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1128\/JVI.78.16.8421-8436.2004","article-title":"Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration","volume":"78","author":"Logan","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0020","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","article-title":"Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery","volume":"72","author":"Zufferey","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0021","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.ymthe.2021.09.001","article-title":"Understanding and overcoming adverse consequences of genome editing on hematopoietic stem and progenitor cells","volume":"29","author":"Lee","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0022","series-title":"FDA approves first gene therapies to treat patients with sickle cell disease","year":"2023"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0023","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jtct.2022.08.029","article-title":"Nomenclature for cellular and genetic therapies: a need for standardization","volume":"28","author":"Sharma","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0024","doi-asserted-by":"crossref","first-page":"636","DOI":"10.5966\/sctm.2013-0206","article-title":"Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases","volume":"3","author":"Williams","year":"2014","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0025","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41467-022-28762-2","article-title":"A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders","volume":"13","author":"Tucci","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0026","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0027","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/B978-0-12-386509-0.00010-7","article-title":"Lentiviral hematopoietic cell gene therapy for X-linked adrenoleukodystrophy","volume":"507","author":"Cartier","year":"2012","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0028","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0029","series-title":"Gene therapy with the lentiviral vector TNS9.3.55 produces long-term improvement in severe \u00df-Thalassemia. 25th Congress of the European Hematology","author":"Maggio","year":"2020"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jcyt.2022.08.003","article-title":"Editing human hematopoietic stem cells: advances and challenges","volume":"25","author":"Bhoopalan","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0031","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","article-title":"Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing","volume":"53","author":"Leibowitz","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0032","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0033","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0034","article-title":"Click editing enables programmable genome writing using DNA polymerases and HUH endonucleases","author":"da Silva","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0035","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","article-title":"Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases","volume":"41","author":"Yarnall","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0036","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0037","series-title":"About sickle cell disease?","year":"2024"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0038","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.15374","article-title":"Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease","volume":"2","author":"Lubeck","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0039","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","article-title":"Allogeneic hematopoietic stem-cell transplantation for sickle cell disease","volume":"361","author":"Hsieh","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0040","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/2040620713483063","article-title":"Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions","volume":"4","author":"Shenoy","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0041","doi-asserted-by":"crossref","first-page":"6062","DOI":"10.1073\/pnas.85.16.6062","article-title":"Expression of the human beta-globin gene following retroviral-mediated transfer into multipotential hematopoietic progenitors of mice","volume":"85","author":"Karlsson","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0042","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1749-6632.1998.tb10472.x","article-title":"Retroviral vectors aimed at the gene therapy of human beta-globin gene disorders","volume":"850","author":"Pawliuk","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0043","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/blood-2007-01-068759","article-title":"Hot spots of retroviral integration in human CD34+ hematopoietic cells","volume":"110","author":"Cattoglio","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0044","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood.2019000949","article-title":"Lentiviral and genome-editing strategies for the treatment of beta-hemoglobinopathies","volume":"134","author":"Magrin","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0045","doi-asserted-by":"crossref","first-page":"e9958","DOI":"10.15252\/emmm.201809958","article-title":"Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives","volume":"11","author":"Naldini","year":"2019","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0046","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1073\/pnas.76.2.670","article-title":"Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S","volume":"76","author":"Nagel","year":"1979","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0047","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0048","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0049","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1182\/bloodadvances.2019001330","article-title":"Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease","volume":"4","author":"Hsieh","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0050","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1182\/blood.2021011488","article-title":"Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither","volume":"138","author":"Jones","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2024.06.002_bib0051","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1182\/blood-2021-147469","article-title":"Safety and efficacy of Aru-1801 in patients with sickle cell disease: early results from the phase 1\/2 Momentum study of a modified gamma globin gene therapy and reduced intensity conditioning","volume":"138","author":"Grimley","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2024.06.002_bib0052","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1182\/blood-2021-152331","article-title":"Clinical results of the Drepaglobe trial for sickle cell disease patients","volume":"138","author":"Magrin","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0053","series-title":"Towards patient specific dosing of melphalan conditioning for ARU-1801, a novel gene therapy for treatment of sickle cell disease. 26th Congress of the European Hematology","author":"Johnson","year":"2021"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0054","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1172\/JCI87885","article-title":"Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype","volume":"126","author":"Brendel","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0055","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0056","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2024.06.002_bib0057","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood-2023-190139","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"142","author":"Frangoul","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0058","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa2215643","article-title":"CRISPR-Cas9 editing of the HBG1 and HBG2 promoters to treat sickle cell disease","volume":"389","author":"Sharma","year":"2023","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2024.06.002_bib0059","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1182\/blood-2023-187397","article-title":"AsCas12a gene editing of HBG1\/2 promoters with EDIT-301 results in rapid and sustained normalization of hemoglobin and Increased fetal hemoglobin in patients with severe sickle cell disease and transfusion-dependent beta-thalassemia","volume":"142","author":"Hanna","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0060","doi-asserted-by":"crossref","first-page":"S238","DOI":"10.1016\/j.jtct.2023.12.312","article-title":"AsCas12a gene editing of HBG1\/2 promoters with EDIT-301 results in rapid and sustained normalization of hemoglobin and increased fetal hemoglobin in patients with severe sickle cell disease and transfusion-dependent beta-thalassemia","volume":"30","author":"Frangoul","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2024.06.002_bib0061","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2022-163725","article-title":"Interim safety and efficacy results from a phase 1\/2 study of zinc finger nuclease-modified autologous hematopoietic stem cells for sickle cell disease (PRECIZN-1)","volume":"140","author":"Alavi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0062","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene autotemcel gene therapy for non-\u03b20\/\u03b20 genotype \u03b2-thalassemia","volume":"386","author":"Locatelli","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0063","series-title":"Gene therapy for the treatment of adult and pediatric patients affected by transfusion dependent beta-thalassemia. American Society of Cell and Gene Therapy Annual Meeting. Washington DC","author":"Ferrari","year":"2019"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0064","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41591-021-01554-9","article-title":"Lentiviral globin gene therapy with reduced-intensity conditioning in adults with \u03b2-thalassemia: a phase 1 trial","volume":"28","author":"Boulad","year":"2022","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2024.06.002_bib0065","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood-2019-125743","article-title":"Preliminary results of a phase 1\/2 clinical study of zinc finger nuclease-mediated editing of BCL11A in autologous hematopoietic stem cells for transfusion-dependent beta thalassemia","volume":"134","author":"Smith","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2024.06.002_bib0066","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2021-147907","article-title":"Updated results of a phase 1\/2 clinical study of zinc finger nuclease-mediated editing of BCL11A in autologous hematopoietic stem cells for transfusion-dependent beta thalassemia","volume":"138","author":"Walters","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0067","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0068","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","article-title":"Hematopoietic stem and progenitor-cell gene therapy for Hurler syndrome","volume":"385","author":"Gentner","year":"2021","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2024.06.002_bib0069","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2022-168672","article-title":"Biochemical engraftment and clinical outcomes following ex-vivo autologous stem cell gene therapy for mucopolysaccharidosis type IIIA","volume":"140","author":"Wynn","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0070","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1089\/hum.1998.9.7-1025","article-title":"Retroviral transfer and long-term expression of the adrenoleukodystrophy gene in human CD34+ cells","volume":"9","author":"Doerflinger","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0071","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0014-5793(99)00379-8","article-title":"Retroviral-mediated adrenoleukodystrophy-related gene transfer corrects very long chain fatty acid metabolism in adrenoleukodystrophy fibroblasts: implications for therapy","volume":"448","author":"Flavigny","year":"1999","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0072","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0073","series-title":"72nd meeting of the cellular, tissue, and gene therapies advisory committee","year":"2022"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0074","first-page":"4S1","article-title":"Myelodysplastic syndromes after Eli-Cel gene therapy for cerebral adrenoleukodystrophy (CALD)","volume":"30","author":"Williams","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0075","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/blood-2017-05-781849","article-title":"Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study","volume":"130","author":"Heimall","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0076","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0077","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0078","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2002-09-2800","article-title":"Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial","volume":"101","author":"Muul","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0079","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0080","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ymthe.2006.06.007","article-title":"Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning","volume":"14","author":"Gaspar","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0081","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa2206575","article-title":"Lentiviral gene therapy for Artemis-deficient SCID","volume":"387","author":"Cowan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0082","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa012616","article-title":"Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy","volume":"346","author":"Hacein-Bey-Abina","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0083","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaci.2020.06.018","article-title":"Gene therapy for Wiskott-Aldrich syndrome: history, new vectors, future directions","volume":"146","author":"Ferrua","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0084","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/mt.2011.166","article-title":"Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I\/II trial","volume":"19","author":"Kang","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0085","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0086","doi-asserted-by":"crossref","first-page":"335ra57","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0087","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0088","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0089","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jaci.2018.08.024","article-title":"Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency","volume":"143","author":"Kohn","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0090","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1538\/expanim.19-0120","article-title":"Generation of novel Il2rg-knockout mice with clustered regularly interspaced short palindromic repeats (CRISPR) and Cas9","volume":"69","author":"Byambaa","year":"2020","journal-title":"Exp Anim"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0091","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41467-019-09614-y","article-title":"Gene correction for SCID-X1 in long-term hematopoietic stem cells","volume":"10","author":"Pavel-Dinu","year":"2019","journal-title":"Nat Commun"},{"issue":"411","key":"10.1016\/j.jcyt.2024.06.002_bib0092","doi-asserted-by":"crossref","first-page":"eaan0820","DOI":"10.1126\/scitranslmed.aan0820","article-title":"Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1","volume":"9","author":"Schiroli","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0093","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nbt.3513","article-title":"Targeted gene addition in human CD34(+) hematopoietic cells for correction of X-linked chronic granulomatous disease","volume":"34","author":"De Ravin","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0094","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1089\/hum.2017.047","article-title":"Comparison of zinc finger nucleases versus CRISPR-specific nucleases for genome editing of the Wiskott-Aldrich syndrome locus","volume":"29","author":"Gutierrez-Guerrero","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0095","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1038\/s41467-020-17626-2","article-title":"Targeted gene correction of human hematopoietic stem cells for the treatment of Wiskott\u2013Aldrich syndrome","volume":"11","author":"Rai","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0096","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/j.celrep.2018.04.103","article-title":"Site-specific gene editing of human hematopoietic stem cells for X-Linked hyper-IgM syndrome","volume":"23","author":"Kuo","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100904","article-title":"A new frontier in Fanconi anemia: from DNA repair to ribosome biogenesis","volume":"52","author":"Gueiderikh","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0098","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/17474086.2016.1268048","article-title":"Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations","volume":"10","author":"Ebens","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0099","doi-asserted-by":"crossref","first-page":"e14835","DOI":"10.1111\/ctr.14835","article-title":"Two decades of stem cell transplantation in patients with Fanconi anemia: analysis of factors affecting transplant outcomes","volume":"37","author":"Fink","year":"2023","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.mt.6300033","article-title":"Stem cell collection and gene transfer in Fanconi anemia","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0101","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1089\/10430349950016988","article-title":"Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC)","volume":"10","author":"Liu","year":"1999","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0102","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/mt.2009.26","article-title":"Lentiviral-mediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi anemia patients","volume":"17","author":"Jacome","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0103","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1182\/blood-2008-05-156356","article-title":"In vivo proliferation advantage of genetically corrected hematopoietic stem cells in a mouse model of Fanconi anemia FA-D1","volume":"112","author":"R\u00edo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0104","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood-2017-03-774174","article-title":"Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34+ cells from Fanconi anemia patients","volume":"130","author":"R\u00edo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0105","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/s41591-019-0550-z","article-title":"Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia","volume":"25","author":"R\u00edo","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0106","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.omtm.2021.06.001","article-title":"Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes","volume":"22","author":"Sevilla","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"Suppl 1","key":"10.1016\/j.jcyt.2024.06.002_bib0107","doi-asserted-by":"crossref","first-page":"10646","DOI":"10.1182\/blood-2022-168342","article-title":"Lentiviral-mediated gene therapy for patients with Fanconi anemia [Group A]: updated results from global RP-L102 clinical trials","volume":"140","author":"Czechowicz","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0108","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.161810","article-title":"An RPS19-edited model for Diamond-Blackfan anemia reveals TP53-dependent impairment of hematopoietic stem cell activity","volume":"8","author":"Bhoopalan","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0109","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3324\/haematol.2020.269142","article-title":"Successful gene therapy of Diamond-Blackfan anemia in a mouse model and human CD34+ cord blood hematopoietic stem cells using a clinically applicable lentiviral vector","volume":"107","author":"Liu","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0110","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1236038","article-title":"Hematopoietic cell transplantation and gene therapy for Diamond-Blackfan anemia: state of the art and science","volume":"13","author":"Bhoopalan","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0111","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1182\/blood.2021013750","article-title":"Editing TINF2 as a potential therapeutic approach to restore telomere length in dyskeratosis congenita","volume":"140","author":"Choo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0112","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3324\/haematol.2019.221804","article-title":"CRISPR\/Cas9-mediated ELANE knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients","volume":"105","author":"Nasri","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0113","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.ymthe.2020.08.004","article-title":"CRISPR-Cas9-mediated ELANE mutation correction in hematopoietic stem and progenitor cells to treat severe congenital neutropenia","volume":"28","author":"Tran","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0114","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/15265161.2019.1665736","article-title":"Should poor social support be an exclusion criterion in bone marrow transplantation?","volume":"19","author":"Sharma","year":"2019","journal-title":"Am J Bioeth"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0115","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1038\/s41467-022-31344-x","article-title":"Lentivector cryptic splicing mediates increase in CD34+ clones expressing truncated HMGA2 in human X-linked severe combined immunodeficiency","volume":"13","author":"De Ravin","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0116","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1101\/gr.162339.113","article-title":"Analysis of off-target effects of CRISPR\/Cas-derived RNA-guided endonucleases and Nickases","volume":"24","author":"Cho","year":"2014","journal-title":"Genome Res"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0117","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target Effects in CRISPR\/Cas9-mediated genome engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0118","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0119","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/nrg.2016.28","article-title":"Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases","volume":"17","author":"Tsai","year":"2016","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0120","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13059-021-02462-4","article-title":"Effective control of large deletions after double-strand breaks by homology-directed repair and dsODN insertion","volume":"22","author":"Wen","year":"2021","journal-title":"Genome Biol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0121","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0122","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.molcel.2016.05.006","article-title":"CRISPR-mediated base editing without DNA double-strand breaks","volume":"62","author":"Plosky","year":"2016","journal-title":"Mol Cell"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0123","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","article-title":"Base editing of haematopoietic stem cells rescues sickle cell disease in mice","volume":"595","author":"Newby","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0124","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajh.26741","article-title":"Lovo-cel gene therapy for sickle cell disease: treatment process evolution and outcomes in the initial groups of the HGB-206 study","volume":"98","author":"Kanter","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.07.017","article-title":"Transplantation after CD45-ADC corrects Rag1 immunodeficiency in congenic and haploidentical settings","volume":"153","author":"Pala","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0126","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/bmb\/ldad017","article-title":"Mobilization-based engraftment of haematopoietic stem cells: a new perspective for chemotherapy-free gene therapy and transplantation","volume":"147","author":"Canarutto","year":"2023","journal-title":"Br Med Bull"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0127","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","article-title":"Epitope editing enables targeted immunotherapy of acute myeloid leukaemia","volume":"621","author":"Casirati","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0128","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0140-6736(71)90998-6","article-title":"Leukaemic transformation of engrafted human marrow cells in vivo","volume":"1","author":"Fialkow","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0129","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.bbmt.2010.10.010","article-title":"Donor cell leukemia: a review","volume":"17","author":"Wiseman","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0130","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/leu.2016.63","article-title":"Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation","volume":"30","author":"Gondek","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0131","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.bbmt.2013.05.022","article-title":"Targeted pathologic evaluation of bone marrow donors identifies previously undiagnosed marrow abnormalities","volume":"19","author":"Tilson","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0132","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/s41375-020-0869-y","article-title":"Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders","volume":"34","author":"Midic","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0133","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2017-02-769869","article-title":"Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly","volume":"130","author":"Zink","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0134","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood-2017-08-801985","article-title":"Somatic mutations and clonal hematopoiesis in congenital neutropenia","volume":"131","author":"Xia","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0135","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/14712598.2022.2124857","article-title":"Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy","volume":"22","author":"Gupta","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0136","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2017-05-783233","article-title":"Increased risk of leukemia among sickle cell disease patients in California","volume":"130","author":"Brunson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0137","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/(SICI)1096-8652(199707)55:4<188::AID-AJH4>3.0.CO;2-O","article-title":"Cancer incidence rate and mortality rate in sickle cell disease patients at Howard University Hospital: 1986\u20131995","volume":"55","author":"Dawkins","year":"1997","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0138","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ajh.10427","article-title":"Malignancy in patients with sickle cell disease","volume":"74","author":"Schultz","year":"2003","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0139","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0141076816651037","article-title":"Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study","volume":"109","author":"Seminog","year":"2016","journal-title":"J R Soc Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0140","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrclinonc.2015.105","article-title":"Inflammation and cancer: advances and new agents","volume":"12","author":"Crusz","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0141","doi-asserted-by":"crossref","first-page":"8129","DOI":"10.3390\/ijms23158129","article-title":"Inflammasomes-new contributors to blood diseases","volume":"23","author":"Tomasik","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0142","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10238-008-0153-3","article-title":"Sensitivity to cisplatin-induced mutations and elevated chromosomal aberrations in lymphocytes from sickle cell disease patients","volume":"8","author":"Alves","year":"2008","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0143","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s00277-023-05294-3","article-title":"Sickle cell disease and acute leukemia: one case report and an extensive review","volume":"102","author":"Cannas","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0144","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-12-756734","article-title":"Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients","volume":"129","author":"Cooper","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2016.11.011","article-title":"Limiting thymic precursor supply increases the risk of lymphoid malignancy in murine X-linked severe combined immunodeficiency","volume":"6","author":"Ginn","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0146","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2010-08-303222","article-title":"Polyclonal fluctuation of lentiviral vector-transduced and expanded murine hematopoietic stem cells","volume":"117","author":"Maetzig","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0147","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/cpt.894","article-title":"Global regulatory differences for gene and cell-based therapies: consequences and implications for patient access and therapeutic innovation","volume":"103","author":"Coppens","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0148","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jcyt.2018.03.038","article-title":"A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: an evaluation of regulatory decision-making","volume":"20","author":"Coppens","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0149","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(24)00175-3","article-title":"Dismantling cost and infrastructure barriers to equitable access to gene therapies for sickle cell disease","author":"Sharma","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0150","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.5966\/sctm.2014-0294","article-title":"Concise review: process development considerations for cell therapy","volume":"4","author":"Campbell","year":"2015","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0151","doi-asserted-by":"crossref","first-page":"e807","DOI":"10.1016\/S2352-3026(22)00327-1","article-title":"Place-of-care manufacturing of gene therapies","volume":"9","author":"Adair","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0152","doi-asserted-by":"crossref","first-page":"16304","DOI":"10.1038\/s41598-018-34601-6","article-title":"TRIAMF: a new method for delivery of Cas9 ribonucleoprotein complex to human hematopoietic stem cells","volume":"8","author":"Yen","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0153","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","article-title":"Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy(R): real-world experience and cost analysis in India","volume":"58","author":"Palani","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.06.002_bib0154","article-title":"Cell therapy products are revolutionizing multiple therapeutic areas; to maintain this pace of innovation, manufacturing solutions must adapt","volume":"20","author":"Abraham","year":"2021","journal-title":"Curr Opin Biomed Eng"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924007357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924007357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T11:11:05Z","timestamp":1728645065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924007357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":154,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1465324924007357"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.06.002","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the current state of hematopoietic stem and progenitor cell\u2013based genomic therapies and the challenges faced","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}